Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tysabri Clear all
Terminated Phase 4 Interventional Results available

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

NCT02241785
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Des Moines, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 22, 2026, 10:25 PM EDT
Terminated Phase 4 Interventional Results available

Natalizumab and Chronic Inflammation

NCT05177718
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab 300 MG in 15 ML Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 22, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

NCT02881567
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
Daclizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Tampa, Florida • Des Moines, Iowa • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

NCT00055367
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Los Angeles, California • Hartford, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

NCT00280956
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational Results available

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Livingston, New Jersey • Portland, Oregon • Richland, Washington + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

NCT01955707
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational

JC-Virus (JCV) Antibody Program

NCT01070823
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri® (natalizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

NCT01071512
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 22, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

NCT01416181
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 22, 2026, 10:25 PM EDT
Active, not recruiting Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2009 · Synced Sep 22, 2026, 10:25 PM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 22, 2026, 10:25 PM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
44
States / cities
Homewood, Alabama • Sun City, Arizona • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

NCT02440126
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

NCT01591551
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab (Tysabri)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Patchogue, New York • High Point, North Carolina • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

NCT04565431
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Tysabri
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

NCT02730455
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 3 Interventional

Open-Label Natalizumab Safety Extension Study

NCT00276172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2009 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational

JC Virus Reactivation in Multiple Sclerosis

NCT02004444
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 22, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

NCT00273364
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 22, 2026, 10:25 PM EDT
Completed No phase listed Observational

Pregnancy Exposure Registry for Tysabri®

NCT00472992
View directory record Official record
Conditions
Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 22, 2026, 10:25 PM EDT